Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01185340 · ClinicalTrials.gov registry record · Phase 3
A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,056
- Enrollment target
NCT01185340 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,056 participants.
The verdict
NCT01185340, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,056 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who are partial responders to their selective serotonin reuptake inhibitor (SSRI) treatment.
Interventions
- DRUG Placebo
- DRUG LY2216684
- DRUG SSRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2011-03 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01185340
The ClinicalTrials.gov registry entry for NCT01185340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01185340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01185340 about?
NCT01185340 is a clinical study titled "A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor". The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who are partial responders to their selective serotonin reuptake ...
What is the current status of trial NCT01185340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,056 participants. The study started on 2011-03. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01185340?
The interventions under investigation include: Placebo (DRUG), LY2216684 (DRUG), SSRI (DRUG).
Who is sponsoring clinical trial NCT01185340?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.